WAVEMAN · COMPANY

HRMY · Harmony Biosciences Holdings, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

HRMY

Name: Harmony Biosciences Holdings, Inc. (HRMY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Harmony Biosciences Holdings, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001802665

FORM 144 · 5☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

184

13F, latest reported quarter

REVENUE GROWTH

+21.5%

XBRL, annual

NET MARGIN

18.3%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

184 funds added or opened last quarter

more than 85% of Pharma & Biotech

REVENUE

+21.5% year over year

more than 70% of Pharma & Biotech

MARGIN

18.3% net margin

more than 88% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

7.7% of shares outstanding short · 5.0 days to cover · settled 2026-07-31

more than 67% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

5 insiders have filed intent to sell ($31.1M) and have not sold yet.

184 funds added or opened positions in the latest 13F quarter, of 330 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +12.8%

+12.8%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 184 funds added last quarter, $31.1M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Harmony Biosciences Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Kapadia Sandip

CHIEF FINANCIAL OFFICER

SELL

2026-01-26

3,746.0

$139.2K

Kapadia Sandip

CHIEF FINANCIAL OFFICER

SELL

2026-01-15

20,961.0

$752.9K

Dayno Jeffrey M.

PRESIDENT, CEO

SELL

2025-12-12

5,933.0

$238.0K

Dayno Jeffrey M.

PRESIDENT, CEO

SELL

2025-12-12

20,000.0

$802.2K

Kapadia Sandip

CHIEF FINANCIAL OFFICER

SELL

2025-12-05

20,000.0

$790.8K

178 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 173 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

7,101,965.0 sh

$258.6M

FMR LLC

3,574,115.0 sh

$130.1M

VANGUARD PORTFOLIO MANAGEMENT LLC

2,880,489.0 sh

$104.9M

AMERICAN CENTURY COMPANIES INC

2,539,512.0 sh

$92.5M

DIMENSIONAL FUND ADVISORS LP

2,393,588.0 sh

$87.1M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

VALOR IV PHARMA HOLDINGS LLC

FILED 2026-08-07

$26.6M

SANDIP KAPADIA

FILED 2026-07-02

$924.0K

SANDIP KAPADIA

FILED 2026-06-30

$1.8M

SANDIP KAPADIA

FILED 2026-06-26

$1.6M

SANDIP KAPADIA

FILED 2026-06-24

$154.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Pharmaceuticals ETF

$10.8M POSITION · AS OF 2026-04-30

3.3%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$5.7M POSITION · AS OF 2026-03-31

1.9%

PROFUND VP PHARMACEUTICALS

$182.2K POSITION · AS OF 2026-03-31

1.8%

AUER GROWTH

$1.1M POSITION · AS OF 2026-02-28

1.6%

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

$187.3K POSITION · AS OF 2026-04-30

1.5%

Bushido Capital US SMID Cap Equity ETF

$2.0M POSITION · AS OF 2026-04-30

1.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · John C. Jacobs

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2020

$3.2M

$6.4M

$2.7M

-2%

+13%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$868.5M	$714.7M	$582.0M	$437.9M
GROSS PROFIT	$670.1M	$557.9M	$460.8M	$354.4M
OPERATING INCOME	$208.5M	$190.8M	$192.0M	$120.2M
NET INCOME	$158.7M	$145.5M	$128.9M	$181.5M
EPS (DILUTED)	2.71	2.51	2.13	2.97
OPERATING CASH FLOW	$348.2M	$219.8M	$219.4M	$144.5M
CASH	$752.5M	$453.0M	$311.7M	$243.8M
LONG-TERM DEBT	$143.7M	$163.0M	$178.6M	$189.6M
BUYBACKS	—	—	$100.0M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE